Our Services
From product development to advocacy, Blue Persimmon can help.
At Blue Persimmon, we offer a comprehensive suite of services at the intersection of innovation and health outcomes.
Medical Product Development
Focusing on lived experience, we establish programs that measure meaningful outcomes to define the value of your healthcare solutions.
- Development plans
- Research design
- Clinical outcome assessments
- Product potential
- Regulatory strategy
Advocacy and Consortia
Blue Persimmon advisors develop advocacy strategies and consortia collaborations to amplify your influence and drive positive change.
- Patient-focused drug development
- Patient Experience Data (PED)
- Research strategies
- Evidence reports
- Public-private partnerships
Health Outcomes Research
We develop the evidence needed to improve health outcomes and inform system-level decisions in healthcare and medical product development.
- Outcomes research
- Real-world evidence
- Health economics
- Health services research
- Survey research
- Qualitative studies
Strategic Guidance
Blue Persimmon advisors guide initiatives and organization leaders to ensure program efficiency, precision, and impact.
- Portfolio assessment
- Resourcing strategy
- Program prioritization
- Long-term planning
- Outsourcing approach
Evidence Submissions
We support submissions to health authorities and real-world audiences to ensure your innovations gain the recognition and support they deserve.
- Stakeholder research
- Advisory boards
- Submission strategy
- Dossier development
- Health authority requirements
Our Work
Rare Kidney Disease Patient Outcome Measure
Disease-specific PRO developed to measure how this population uniquely experiences and reports pain.
Societal Costs of Schizophrenia
Partnered with a Non-profit Organization to model full systems impacts of disease to support policy and research decisions.
Priorities in Alzheimer's
A multi-year effort led by a Non-Profit Organization focused on priorities of those most impacted by Alzheimer’s Disease.
Rare Disease Natural History
Combined government and private sector data to maximize learning potential for a treatment in a rare disease population.